Compare IDEXX Laboratories, Inc. (IDXX) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Schwab US Dividend Equity ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Schwab US Dividend Equity ETF trades at $33.04 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is far larger — about 2.7× IDEXX Laboratories, Inc.'s market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| IDXX | SCHD | |
|---|---|---|
Market Cap | $40.43B | $110.56B |
Volume | 692,164 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $35.21 |
52-Week Low | $504.70 | $26.44 |
Typical Hold Time | 46 Days | 62 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
SCHD trades at $33.15, up 1.53% today, with a bullish technical signal despite mixed moving averages. The ETF shows strong dividend focus, with recent news highlighting its 2026 outperformance over the S&P 500. Support levels cluster around $33, while resistance sits at $34. Dividend payments continue with a $0.27 distribution scheduled for September 2026.
SCHD offers income-focused investors exposure to high-quality U.S. dividend stocks with defensive characteristics. Key risks include interest rate sensitivity and potential missed growth opportunities from strict selection criteria. The ETF's consistent dividend growth and lower fee structure provide competitive advantages in the income ETF space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
